The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.
 
Mariane Sousa Fontes
No Relationships to Disclose
 
Nikolaos Diamantis
No Relationships to Disclose
 
Niamh Coleman
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
L Rhoda Molife
No Relationships to Disclose
 
Manolo D'Arcangelo
No Relationships to Disclose
 
Analia Azaro
No Relationships to Disclose
 
Gareth J Veal
No Relationships to Disclose
 
Elisabet Sicart
No Relationships to Disclose
 
Ander Urruticoechea
Consulting or Advisory Role - Eisai; Roche/Genentech
Travel, Accommodations, Expenses - Eisai; Novartis; Roche; Sysmex
 
Pablo V. Escriba
Employment - Lipopharma
Honoraria - Lipopharma
Consulting or Advisory Role - Lipopharma
Travel, Accommodations, Expenses - Lipopharma
 
Xavier Busquets
Employment - Lipopharma
 
Antoine Perier
No Relationships to Disclose
 
Vicente Tur
Employment - Lipopharma
Leadership - Lipopharma
Stock and Other Ownership Interests - Lipopharma
Honoraria - Lipopharma
 
Juanita Lopez
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Lilly/ImClone; Novartis; SERVIER
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech